Patent ID: 8669261
Filing Date: 2014-03-11
Classification: A61P,C07C,C07D

Abstract:
1. A method for the treatment of a disease or condition associated with the activity of the mitochondrial permeability transition pore (MPTP) in a subject afflicted therewith comprising administering to the subject a compound of the general formula (I) wherein: W is aryl or heteroaryl; a is 0, 1, 2, or 3; R and R′ are the same or different and, independently from each other, is: hydrogen; halogen; (C1-C3)alkoxy; (C1-C2)haloalkoxy; (C1-C2)haloalkyl; NR R″ is: with the proviso that: when W is phenyl, a is 1, 2 or 3; when W is phenyl and R is hydrogen, R″ is other than chlorine, methyl, isopropyl, CF when W is indazol-5-yl or pyrid-2-yl, R is other than hydrogen, (C1-C3)alkoxy; or a tautomer, a racemate, an enantiomer, a diastereomer, an epimer, a mixture thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof, and wherein the disease or condition associated with the activity of the mitochondrial permeability transition pore (MPTP) is myocardial infarction, heart failure, organ ischemia, ischemic and traumatic brain damage, Duchenne muscular dystrophy, Ullrich congenital muscular dystrophy, Bentham myopathy, amyotrophic lateral sclerosis, Huntington's disease, Alzheimer's disease, Parkinson's disease, diabetes type I and type II, diabetic complications, hyperglycemic tissue damage, hypoglycemic tissue damage, cholestasis, or alcohol-induced damage.